Introduction
dominant syndrome [10] [11] . AMPK is composed of a catalytic subunit (␣1 and ␣2) and regulatory subunits (␤1, ␤2, ␥1, ␥2 and ␥3). It is activated in response to modulation of AMP/ATP ratio under stress conditions and also by certain cytokines and hormones like leptin and adiponectin [12] . Pharmacological compounds like aminoimidazole carboxamide ribonucleotide (AICAR), thiazolidinediones (TZDs), metformin and A-769662 also activate AMPK [13] .
Recently, the role of AMPK in inhibiting proliferation has received attention in tumours of diverse origins [14] . AMPK is involved in cell cycle regulation, protein synthesis and modulates p53-p21 and TSC-2-mTOR nexus, respectively [15] . AMPK activation has been shown to also down-regulate PI3K-Akt pathway in cancer cells [16] 
. An alternate mechanism by which AMPK can exert anti-growth activity is through inhibition of lipid biosynthesis via inhibition of the acetyl co-carboxylase (ACC), a rate limiting enzyme of the fatty acid synthesis pathway [12]. Very little is known on the status of AMPK (basal enzymatic activity and the expression of its various subunits/isoforms) and use of metformin as a potential chemotherapeutic drug in ovarian cancer either in vivo or in vitro.
In the present study, we show that metformin inhibits ovarian cancer cell proliferation by modulating diverse pathways including inhibition of cell cycle, survival pathways, and /or protein and lipid biosynthetic pathways. Our studies also indicate that metformin can inhibit ovarian cancer cell growth in an AMPK dispensable manner. 
Material and methods

Reagents and antibodies
Metformin, trypan Blue, MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), and propidium iodide were all from Sigma (St. Louis, MO, USA). C14-methionine, C14-palmitic acid and C14-acetate were purchased from American Radiolabeled Chemicals (St. Louis, MO, USA). Antibodies to AMPK␣1 was from Epitomics
Cell culture
Ovarian cancer cell lines, OVCAR3, OVCAR5 and CaOv3 were from ATCC (Manassas, VA, USA) and grown according to accompanied instructions.
OV202 is a low passage primary cell line generated at Mayo Clinic and grown in DMEM [17] . A2780 
Western blot
Immunoblot analysis with specific antibodies was performed as previously described [16] . Fig. S2 . Collectively, these results suggest that metformin inhibits cell cycle progression by modulating the expression of cell cycle proteins.
Protein synthesis
2). These results suggest that metformin treatment can result in a sustained inhibition of proliferation of various ovarian cancer cell lines, including chemoresistant cell lines (CP70, C200 and PE04) (Fig. 2B, C and F). To check the effect of metformin on primary ovarian cells, we treated a SV40t/T immortalized ovarian surface epithelial cell line, IOSE-523 with metformin for 3 days. Metformin treatment (5-20 mM) did not have any significant effect on the growth of IOSE-523 cells, suggesting that its anti-proliferative effect is specific to ovarian cancer cells (Fig. S1A). HeLa cells treated with the same increasing doses of metformin (5-20 mM) for 3 days did not show any significant decrease in cell viability (Fig. S1B) indicating that the concentrations used in this study are not toxic to the cells.
Metformin causes cell cycle arrest in G1-phase
To determine if metformin-mediated inhibition of cell proliferation may reflect changes in cell cycle, we examined cell cycle distribution by flow cytometry. As depicted in Fig. 3A, metformin treatment led to accumulation of cells in G1-phase with corresponding decrease in the percentage of cells in the S-phase in all ovarian cancer cell lines tested compared to untreated cells. Consistent with this G1 arrest, immunoblot analysis revealed that metformin treatment resulted in reduced cyclin D1 levels with concomitant increase in the expression of p21 in A2780, CP70, C200 and SKOV3ip cells; however, there was no change in the expression of p27 (Fig. 3B). Densitometric representation of the data is shown in
Metformin activates AMPK in ovarian cancer cells
Immunoblot analysis of expression of AMPK subunits showed that AMPK␣1 and ␤1 subunits were the predominant isoforms expressed in several ovarian cancer cell lines. ␥1 and ␥2 subunits were variably expressed, whereas ␥3 was not detected (Fig. S3) . (Fig. 4A) . ACC is an important rate-controlling enzyme for the synthesis of malonyl-CoA, which is a critical precursor for biosynthesis of fatty acids and also a potent inhibitor of mitochondrial fatty acid oxidation [20] . Metformin treatment significantly enhanced the mitochondrial ␤-oxidation, further supporting the activation of AMPK and inhibition of ACC in A2780, CP70 and C200 cells (Fig. 4B ).
With the exception of CaOV3, LKB1 was expressed in all tested cell lines, indicating that the LKB1-AMPK pathway is intact in most ovarian cancer cell lines. Because metformin treatment results in the activation of AMPK, we determined its effect on AMPK activity in various ovarian
Metformin inhibits m-TOR-S6RP-protien translation and lipid biosynthetic pathways
AMPK activation is associated with decreased activation of mTOR and S6K, a critical translational pathway for protein synthesis [21, 22] . Metformin [25, 26] [4] [5] [6] and more recently in ovarian and pancreatic cancer cells [7, 8] (Fig. 1D) [36, 37] . We speculate that one or more of these downstream kinases may play a role in inducing cell cycle arrest in the absence of AMPK. Also, LKB1 by itself can cause G1 cell arrest [38, 39] . LKB1 mutant cells also have been shown to have increased expression of Cyclin D1 [39] and LKB1 has a direct role in transcriptional up-regulation of p21 via p53 in a promoter specific manner [40, 41] . This suggests that LKB1, on activation, can cause cell cycle arrest independent of its activity on AMPK. Conversely, it may be that metformin as a drug has some direct effect in modulating cell cycle. In support of this, Isakovic et al., showed metformin treatment caused G0/G1 cell cycle arrest resulting in apoptosis via mitochondrial depolarization and oxidative stress in glioma C6 cells while having no effect on primary astrocytes [5] .
In recent years, various studies have shown that metformin has anti-tumour properties in vitro and in vivo. In vitro anti-proliferative effects of metformin have been reported in cancers of the breast, glioma, prostate and colon
It is interesting to note that although metformin treatment resulted in the inhibition of Cyclin D1 and activated p21 in SKOV3ip1 cells, it did not inhibit proliferation
The mechanism by which metformin activates AMPK is not well understood. It is reported that metformin inhibits complex I of respiratory chain leading to an increase in the AMP levels which in turn leads to LKB1-AMPK activation [42] . Because 
